AstraZeneca is a company with a turbulent history but, for now, a promising future. We take a look at the company's story, from its creation as a merger of two equals, to its recent major ...

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () (NasdaqGS:AZN) from Neutral to Buy. Analyst Price Forecast Suggests 13.43% Upside As of ...